Description

• Continuum Feline Bb is an intranasal vaccine containing an avirulent live culture of Bordetella bronchiseptica

Indications

• Continuum Feline Bb is for the vaccination of healthy kittens and cats for prevention of disease caused by B. bronchiseptica

Efficacy and Safety

• Patented and specifically formulated for use in cats
• Over 92% effective with one dose at 4 weeks of age, as demonstrated in challenge studies conducted 3 weeks postvaccination¹
• Aids in the prevention of disease caused by B. bronchiseptica 72 hours after vaccination of 8-week-old kittens, as demonstrated in onset-of-immunity studies
• Intranasal vaccination with Continuum Feline Bb stimulates rapid, local immunity in the respiratory tract, thereby inhibiting infection at the port of entry as well as preventing clinical signs
• Small volume (0.2 mL) and one-nostril application provide for ease in vaccination
• Greater than 98% reaction free in cats from 4 weeks to 16 years of age¹
• May be safely administered to healthy kittens as young as 4 weeks of age
• Safe for pregnant queens

Directions for Use

• Remove the needle and administer 0.2 mL into one nostril intranasally
• Healthy kittens 4 weeks of age or older should be vaccinated prior to confinement or when risk of exposure to B. bronchiseptica may exist
• Healthy kittens 8 weeks of age or older are protected as early as 72 hours postvaccination
• Annual revaccination with a single dose is recommended

Reference:
1. Data on file, Merck Animal Health